One of the main obstacles to establishing Good Manufacturing Practice (GMP) facilities in the UK is the cost and the reluctance of pharmaceutical firms to invest in phages and antimicrobials more generally because of an uncertain return on investment compared to other medicines and drugs. However, investing in a small, or shared multi-use, GMP facility is one possible solution to ensure that such capacity could be run cost effectively. The allocation of public funds to establish a GMP facility could be offset by savings delivered to the NHS, by avoiding wasted antibiotics and unnecessary surgery resulting from AMR. Such a facility could also supply phages to non-health sectors which could be used to cross-subsidise healthcare phages.